We are live on ! Find out more
IRD

Opus Genetics
IRD

28 hedge funds and large institutions have $3.28M invested in Opus Genetics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

33% more funds holding

Funds holding: 21 → 28 (+7)

26% less capital invested

Capital invested by funds: $4.44M → $3.28M (-$1.15M)

Holders
28
Holders Change
+7
Holders Change %
+33.33%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
2
Closed
2
Calls
$56K
Puts
–
Net Calls
+$56K
Net Calls Change
-$23K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$298K
2
BCM
Bridgeway Capital Management
Texas
+$106K
3
Bank of America
Bank of America
North Carolina
+$40.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$39.6K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$38.6K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$681K
2
SM
Sabby Management
Florida
-$411K
3
Wells Fargo
Wells Fargo
California
-$16.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Quebec, Canada
$406 – – –
SM
27
Sabby Management
Florida
– -$411K -3,540 Closed
1
2

IRD Hedge Fund Activity: Q4 2017 in Review

28 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2017, worth a combined $3.28M — down 26% from $4.44M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IRD positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $298K. The largest seller was Renaissance Technologies, cutting an estimated $681K.

  • 28 institutional investors held Opus Genetics (IRD) as of Q4 2017, up from 21 in Q3 2017.
  • Funds reported $3.28M of Opus Genetics stock for Q4 2017, down 26% quarter-over-quarter.
  • 9 funds opened new Opus Genetics positions in Q4 2017 and 2 closed out, a net change of +7 holders.
  • The largest Opus Genetics buyer in Q4 2017 was Vanguard Group, an estimated $298K added.
  • The largest Opus Genetics seller in Q4 2017 was Renaissance Technologies, an estimated $681K sold.

Based on aggregated 13F filings for Q4 2017.